Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years

Summary

The purpose of this study is to evaluate the effectiveness and safety of paliperidone extended release (ER) in symptomatic participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) who were receiving treatment with any oral (having to do with the mouth) antipsychotic medication and who needed to be switched to paliperidone ER from the current oral antipsychotic therapy due to insufficient efficacy or due to side effects.

Timeline

Start

2009-01

Primary completion

2010-03

Completion

2010-03

Drugs

Indications